1. Home
  2. MAIA vs PED Comparison

MAIA vs PED Comparison

Compare MAIA & PED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • PED
  • Stock Information
  • Founded
  • MAIA 2018
  • PED N/A
  • Country
  • MAIA United States
  • PED United States
  • Employees
  • MAIA N/A
  • PED N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • PED Oil & Gas Production
  • Sector
  • MAIA Health Care
  • PED Energy
  • Exchange
  • MAIA Nasdaq
  • PED Nasdaq
  • Market Cap
  • MAIA 56.3M
  • PED 48.8M
  • IPO Year
  • MAIA 2022
  • PED N/A
  • Fundamental
  • Price
  • MAIA $1.70
  • PED $0.63
  • Analyst Decision
  • MAIA
  • PED Strong Buy
  • Analyst Count
  • MAIA 0
  • PED 1
  • Target Price
  • MAIA N/A
  • PED $1.50
  • AVG Volume (30 Days)
  • MAIA 468.1K
  • PED 114.7K
  • Earning Date
  • MAIA 08-08-2025
  • PED 08-13-2025
  • Dividend Yield
  • MAIA N/A
  • PED N/A
  • EPS Growth
  • MAIA N/A
  • PED 2248.88
  • EPS
  • MAIA N/A
  • PED 0.19
  • Revenue
  • MAIA N/A
  • PED $40,173,000.00
  • Revenue This Year
  • MAIA N/A
  • PED N/A
  • Revenue Next Year
  • MAIA N/A
  • PED $5.99
  • P/E Ratio
  • MAIA N/A
  • PED $3.31
  • Revenue Growth
  • MAIA N/A
  • PED 30.70
  • 52 Week Low
  • MAIA $1.40
  • PED $0.47
  • 52 Week High
  • MAIA $3.74
  • PED $1.07
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 44.78
  • PED 46.64
  • Support Level
  • MAIA $1.64
  • PED $0.62
  • Resistance Level
  • MAIA $1.74
  • PED $0.65
  • Average True Range (ATR)
  • MAIA 0.09
  • PED 0.03
  • MACD
  • MAIA -0.01
  • PED -0.00
  • Stochastic Oscillator
  • MAIA 11.76
  • PED 64.59

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.

Share on Social Networks: